ArticleDigestive diseases and sciences2026
Do Improving Hepatic Biomarkers Predict Spontaneous Stone Passage? A Retrospective Analysis of ERCP Yield in Suspected Choledocholithiasis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholedocholithiasis (CDL) is a common indication for endoscopic retrograde cholangiopancreatography (ERCP). While guidelines use static hepatic biomarker values to estimate pre-test probability, the utility of trending these labs (bilirubin and alkaline phosphatase [ALP]) is unclear. It is unknown if improving biomarker trends reliably indicate stone passage and can help avoid unnecessary procedures.
objectiveTo evaluate whether serial trends in hepatic biomarkers prior to ERCP can predict the presence of suspected CDL in hospitalized patients and guide decisions on ERCP referral.
methodsWe conducted a retrospective study of 198 patients undergoing ERCP for suspected CDL from 2002 to 2018. Patients were categorized based on biomarker trends, primarily into: Group 1 (normalized bilirubin with normalized ALP or ALP falling ≥ 50%) and Group 2 (all other patients). The primary outcome was the diagnostic yield of CDL on ERCP.
resultsAmong 198 patients, the yield of choledocholithiasis was not significantly different between Group 1 (69.5%) and Group 2 (71.2%) (p = 0.83). Even when redefining Group 1 as patients with "entirely normal hepatic biomarkers," the yield for stones was 55%. The diagnostic accuracy of the final lab values was poor, with an area under the curve of 0.57 for bilirubin and 0.51 for ALP. Patients in Group 1 had a significantly higher rate of post-ERCP pancreatitis (8.5% vs. 0%, p = 0.012) and a lower risk of septic shock.
conclusionsNormalization or decline in hepatic biomarkers, such as bilirubin and ALP, does not reliably exclude CDL. Over half of the patients with normalized biomarkers were still found to have stones on ERCP. ERCP should be considered when suspicion remains high, regardless of laboratory trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.